Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Patch Clear all
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phototoxicity Test of Dapsone Gel in Healthy Volunteers

NCT02108483
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dapsone gel, dapsone gel vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

NCT04882631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PBI-100 Topical Cream, Positive Control - Sodium laurel sulfate (SLS), PBI-100 Topical Cream, Vehicle, Negative Control
Drug · Other
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newtown Square, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Fluphenazine Hydrochloride for Psoriasis

NCT00929578
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

NCT01962987
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Fremont, California • Long Beach, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RIPT of Ibuprofen Topical Gel

NCT01787448
View directory record Official record
Conditions
Pain
Interventions
Topical gel vehicle, Sodium lauryl sulfate 0.1%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients

NCT03377803
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Study of SOR007 Ointment for Actinic Keratosis

NCT03083470
View directory record Official record
Conditions
Actinic Keratosis
Interventions
SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle
Drug · Other
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
45 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 5, 2026, 4:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients-1

NCT03377790
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
18
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers

NCT00605956
View directory record Official record
Conditions
Head Lice
Interventions
NatrOVA Creme Rinse - 1%, NatrOVA Creme Rinse Vehicle Only, Blank Patch
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Sep 5, 2026, 4:09 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Topical Safety Study of Topical Diltiazem Hydrochloride

NCT01816529
View directory record Official record
Conditions
Diltiazem Skin Sensitivity.
Interventions
Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%)
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

NCT02062073
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate, saline 0.9%, Vehicle Lotion
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face

NCT04085367
View directory record Official record
Conditions
Actinic Keratoses
Interventions
MAL 16.8% cream, MAL Vehicle Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
59
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Encinitas, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

NCT02117752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeat Insult Patch Test of Wound Dressings

NCT01368146
View directory record Official record
Conditions
Skin Sensitization
Interventions
IV Clear™, Tegaderm CHG™, Silicone Vehicle Control Dressing
Device
Lead sponsor
Covalon Technologies Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

NCT04155203
View directory record Official record
Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
Mupirocin Calcium, Vehicle
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Months and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 5, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NCT05799157
View directory record Official record
Conditions
Verruca Vulgaris, Warts, Common Wart
Interventions
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
9 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 5, 2026, 4:09 AM EDT